LXRX · XBRL financial data

Lexicon Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LXRX's year ends in late December)

In millions of dollars	FY 2019Dec 31, 2020	FY 2019Dec 31, 2021	FY 2019Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	24	0	0	1	31	50
Revenue from contracts with customers	23	0	0	1	6	—
Cost of goods and services sold	2	0	0	0	1	0
Research and development	154	55	53	59	84	61
Selling, general and administrative	—	32	48	114	143	37
General and administrative	47	32	48	—	—	—
Total operating expenses	204	87	101	—	—	—
Operating income (loss)	(48)	(87)	(101)	(172)	(197)	(49)
Interest expense	15	1	3	—	—	—
Other income (expense)	3	0	2	8	12	7
Income tax expense (benefit)	—	0	0	0	0	—
Net income (loss)	(59)	(88)	(102)	(177)	(200)	(50)
Earnings per share, basic USD per share	(0.53)	(0.60)	(0.62)	(0.80)	(0.63)	(0.14)
Earnings per share, diluted USD per share	(0.53)	(0.60)	(0.62)	(0.80)	(0.63)	(0.14)
Weighted average shares, basic millions of shares	—	146	166	221	320	363
Weighted average shares, diluted millions of shares	111	146	166	221	320	363

Fiscal years (LXRX's year ends in late December)

In millions of dollars	FY 2019Dec 31, 2020	FY 2019Dec 31, 2021	FY 2019Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	126	64	46	22	67	34
Short-term investments	26	23	92	148	171	62
Marketable securities	—	—	92	148	171	62
Accounts receivable	0	0	0	1	3	2
Inventory	0	—	0	0	0	0
Total current assets	158	89	141	177	246	102
Property and equipment, net	0	1	2	2	2	2
Right-of-use asset	1	2	7	6	5	7
Goodwill	45	45	45	45	45	45
Total assets	204	137	194	229	298	185
Accounts payable	5	9	10	14	15	3
Accrued liabilities	30	13	13	17	30	13
Current portion of long-term debt	12	0	—	—	0	5
Total current liabilities	47	22	23	32	45	21
Long-term debt	0	0	49	100	100	49
Lease liability, non-current	—	—	5	5	5	7
Total liabilities	47	23	77	136	152	77
Accumulated deficit	(1,400)	(1,488)	(1,590)	(1,767)	(1,967)	(2,018)
Total stockholders' equity	156	114	117	93	146	108
Total liabilities and equity	204	137	194	229	298	185
Common shares outstanding (cover page) millions of shares	144	—	189	246	361	424

Fiscal years (LXRX's year ends in late December)

In millions of dollars	FY 2019Dec 31, 2020	FY 2019Dec 31, 2021	FY 2019Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(59)	(88)	(102)	(177)	(200)	(50)
Stock-based compensation	13	11	12	14	13	13
Depreciation and amortization	3	0	0	1	1	1
Net cash from operating activities	(143)	(87)	(89)	(162)	(179)	(68)
Purchases of property and equipment	0	1	1	0	1	0
Net cash from investing activities	381	2	(71)	(50)	(15)	113
Proceeds from issuing common stock	70	37	94	139	0	0
Share repurchases	1	3	1	1	2	—
Proceeds from long-term debt	0	—	49	50	0	0
Repayments of long-term debt	217	12	(49)	—	—	—
Net cash from financing activities	(148)	23	142	188	238	(48)
Net change in cash	—	(62)	(18)	(24)	44	(3)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Lexicon Pharmaceuticals	41	0.7	(9.2)*	445.0M	20.7 quarters	Q2 FY26 10-QJun 30, 2026
XOMA Royalty	86	12	6.1	12.5M	—	Q1 FY26 10-QMar 31, 2026
Omeros	2	29	4.1*	72.4M	—	Q2 FY26 10-QJun 30, 2026
Astria Therapeutics	96	0.7	(32)*	57.1M	7.1 quarters	Q3 FY25 10-QSep 30, 2025
4D Molecular Therapeutics	70	3.8	(70)*	55.2M	5.2 quarters	Q2 FY26 10-QJun 30, 2026
Crescent Biopharma	172	0	(19)*	37.1M	8.8 quarters	Q2 FY26 10-QJun 30, 2026
Lineage Cell Therapeutics	37	1.1	(7.2)*	252.9M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Forte Biosciences	50	not reported	(23)*	21.2M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
Monopar Therapeutics	53	0*	(3.2)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.